Euphoriants

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

NEOGEN Launches Reveal® Q+ for Δ9-THC in Hemp

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Psychoactive drugs, Euphoriants, Appetite stimulants, Entheogens, Organ systems, Cannabis, Cannabinoids, Tetrahydrocannabinol, Hemp, Cannabidiol

NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.

Key Points: 
  • NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.
  • "The addition of the ability to test for 9-THC to our Reveal Q+ portfolio puts the power in the hands of hemp farmers," says John Adent, NEOGEN's President and CEO.
  • Hemp has various uses, including rope and textiles, feed and grain, and cannabidiol (CDB), commonly used in body care products and supplements.
  • NEOGEN Corporation develops and markets comprehensive solutions dedicated to food and animal safety.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

PALM BEACH, Fla., July 28, 2021 /PRNewswire/ -- Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health. Increasing consumer disposable income along with the legalization of medicinal cannabis is anticipated to have a positive impact on the demand for cannabidiol in the pharmaceutical sector. Oils, tinctures, concentrate, capsules, topical solutions such as slaves, lip balms, lotions, and edibles such as baked goods, coffee, chocolates, gums, and candies are some of the CBD products which are in high demand. Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products.  A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.  Active Companies in the merchant industry include Grove, Inc. (NASDAQ: GRVI), Tilray, Inc. (NASDAQ: TLRY) (TSX: TLRY), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Pressure BioSciences, Inc. (OTCQB: PBIO), cbdMD, Inc. (NYSE: YCBD).

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

Doobie Brings Medical Marijuana Delivery to Missouri

Retrieved on: 
Wednesday, July 28, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Dispensary, Health sciences, Drugs in the United States

ST. LOUIS, July 28, 2021 /PRNewswire/ -- Doobie, a leading cannabis delivery service, is pleased to announce that it is entering the Missouri market to provide services to medical marijuana patients.

Key Points: 
  • ST. LOUIS, July 28, 2021 /PRNewswire/ -- Doobie, a leading cannabis delivery service, is pleased to announce that it is entering the Missouri market to provide services to medical marijuana patients.
  • In partnership with JANE Dispensary , located in the Delmar Loop in St. Louis, Doobie will be the first company to provide medical marijuana delivery in the state.
  • Doobie's co-founder Joseph Rubin says "We're proud to be the first delivery company to provide medical marijuana to patients in Missouri.
  • Missouri medical marijuana regulations require that all cannabis orders be paid for before they go out for delivery.

Shatterizer inc. launches their newest edition to the family, the BUBBLER by Shatterizer

Retrieved on: 
Wednesday, July 28, 2021
Cannabis smoking, Psychoactive drugs, Health sciences, Pharmacology, Euphoriants, Drug paraphernalia, Dosage forms, Cannabis, Vaporizer, Bubbler

Toronto, ON, July 28, 2021 (GLOBE NEWSWIRE) -- Shatterizer inc. is pleased to announce their revolutionary portable and desktop cannabis extracts vaporizer, the BUBBLER by Shatterizer .

Key Points: 
  • Toronto, ON, July 28, 2021 (GLOBE NEWSWIRE) -- Shatterizer inc. is pleased to announce their revolutionary portable and desktop cannabis extracts vaporizer, the BUBBLER by Shatterizer .
  • In 2021, Shatterizer aims to surpass expectations with their newest product, the BUBBLER by Shatterizer .
  • The BUBBLER by Shatterizer is the most innovative cannabis concentrate vaporizer to hit the market.
  • We believe in delivering market disrupting products, and we personally love the BUBBLER by Shatterizer, expect even more #PerfectClouds in 2021!

CampNova Announces Sourcing and Retail Partnerships for 2 Chainz' GAS Cannabis Brand

Retrieved on: 
Wednesday, July 28, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Psychoactive drugs, Medicine

LOS ANGELES, July 28, 2021 /PRNewswire/ -- CampNova has created a partnership with titan cannabis cultivator, Vertical Companies, to source premium cannabis flower for 2 Chainz' GAS Cannabis brands .

Key Points: 
  • LOS ANGELES, July 28, 2021 /PRNewswire/ -- CampNova has created a partnership with titan cannabis cultivator, Vertical Companies, to source premium cannabis flower for 2 Chainz' GAS Cannabis brands .
  • The technology platform also announced Hellapax and Smoke on the Water as the primary delivery service exclusively for GAS Cannabis.
  • The definitive agreements call for a strategic partnership expected to accelerate the access and availability of GAS Cannabis in CampNova's direct-to-consumer strategies.
  • The goal of both companies is to further align other delivery and retail partnerships while creating more minority business partnerships with GAS Cannabis .

New to The Street Signs 12 Part TV Series To Feature Global Wellness Strategies, Inc.; Filming Started Week of July 26, 2021

Retrieved on: 
Tuesday, July 27, 2021
Psychoactive drugs, Drugs, Entheogens, Euphoriants, Herbalism, Medicinal plants, Cannabis, Cannabis smoking, MDMA, Hemp, Newsmax

Throughout the series, Ms. Kott introduces the companys other subsidiaries which produce hemp and medicinal-mushroom infused CBD products for consumers .

Key Points: 
  • Throughout the series, Ms. Kott introduces the companys other subsidiaries which produce hemp and medicinal-mushroom infused CBD products for consumers .
  • Global Wellness Strategies, Inc. offers a range of MDMA-based novel treatments that we believe can solve the chronic pain problems of millions.
  • Filming begins later the week of July 26, 2021 with New to The Street host Jane King .
  • The Newsmax New to The Street TV show is syndicated on Sundays at 10 AM EST.

Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA

Retrieved on: 
Tuesday, July 27, 2021
Mental health, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Drug rehabilitation, Drugs, Psychoactive drugs, Synthetic opioids, Ketones, Substance dependence, Medical specialties, Euphoriants, Methadone, Levomethadone, Opioid use disorder, Opioid, LYN-014, Opioid Use Disorder, Lyndra Therapeutics, LYN-014, OPIOID USE DISORDER, LYNDRA THERAPEUTICS

A weekly dosage form would free people from daily trips to methadone clinics and support consistency of treatment, recovery and wellbeing.

Key Points: 
  • A weekly dosage form would free people from daily trips to methadone clinics and support consistency of treatment, recovery and wellbeing.
  • The FDAs decision to grant LYN-014 Fast Track designation speaks to their commitment to provide people living with OUD with new, innovative treatment options.
  • LYN-014, which was granted investigational new drug status in April, is set to begin a Phase 1 clinical trial this quarter.
  • LYN-014, Lyndras investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).

Biomedican Receives Approval Notification From the U.S. Patent Office on Its 1st Patent

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Euphoriants, Cannabinoid, Psychoactive drugs, Appetite stimulants, Entheogens, Yarrowia, Tetrahydrocannabinol, Patent, Branches of biology

SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Biomedican has received notification from the U.S. patent office that its first patent has been approved and will be issued in the coming months.

Key Points: 
  • SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Biomedican has received notification from the U.S. patent office that its first patent has been approved and will be issued in the coming months.
  • This is the first patent ever to be issued using Yarrowia Lipolytica to produce cannabinoids.
  • Enzymes which are converting CBGA into CBDA, CBCA and THCA are required for the presence of interaction of two phases: oil and water.
  • "Patenting the use of Yarrowia Lipolytica to produce cannabinoids gives Biomedican a significant competitive advantage in the biosynthesized cannabinoid market.

DELIC Labs President and CSO Dr. Markus Roggen to Speak at MJBizCon

Retrieved on: 
Tuesday, July 27, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Branches of biology, Mycotoxins, Organophosphates, Psilocybin, Plants, Cannabis, Roggen

"Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs," said Dr. Roggen, DELIC Labs President and CSO.

Key Points: 
  • "Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs," said Dr. Roggen, DELIC Labs President and CSO.
  • Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization.
  • Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development.
  • Delic Labs is one of a handful of research labs licensed for both cannabis and psilocybin in Canada.